Authors
Zhenfei Hong, Feng Dong
Published in
Archives of physiology and biochemistry. Pages 1-14. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis and can progress to steatohepatitis. Netrin-3, an axon guidance protein linked to metabolic homeostasis, has not been characterized in MAFLD.
MAFLD was induced in mice by high-fat diet. Netrin-3 and UNC5A expression was measured in serum and liver. Recombinant Netrin-3 was administered with or without Compound C. Hepatic AMPK/ACC phosphorylation, PPARα and target genes, lipid and glucose profiles, insulin, and liver injury were assessed. AML12 hepatocytes with fatty acid overload were treated with Netrin-3, Compound C, or AMPKα siRNA.
Netrin-3 and UNC5A were downregulated in MAFLD mice. Netrin-3 treatment reduced body weight, adiposity, dyslipidemia, hyperglycemia, hyperinsulinemia, ALT/AST levels, and hepatic steatosis. It increased AMPK and ACC phosphorylation and restored PPARα, Fabp1, and CPT1α expression. Compound C reversed these protective effects in vivo. In AML12 cells, Netrin-3 activated AMPK/ACC signaling, and this effect was abolished by Compound C and AMPKα siRNA.
Netrin-3 attenuates MAFLD progression by activating the hepatic AMPK-PPARα axis and promoting fatty acid oxidation, identifying Netrin-3 as a candidate therapeutic molecule for fatty liver disease.
PMID:
43043069
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0